Floatz logo

Trastuzumab Deruxtecan

Advanced Breast Carcinoma

SWOG Cancer Research Networkantibody_drug_conjugatePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
89/ 100

Competitive context

224 Active assets in the Advanced Breast Carcinoma cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
SWOG Cancer Research Network
Phase 4BBB
Zoledronate
Washington University School of Medicine
Phase 4BBB
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 3BBB
TAMOXIFEN
Dartmouth-Hitchcock Medical Center
Phase 4BBB
TAMOXIFEN
Xijing Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

HER2-low Expressing Breast CancerDormant
BBB
Indicative ·
77 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
66 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →